Changeflow GovPing Healthcare & Life Sciences PRMT5 inhibitors for cancer treatment
Routine Notice Added Final

PRMT5 inhibitors for cancer treatment

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO granted patent US12595248B2 to Merck Sharp & Dohme LLC covering PRMT5 inhibitor compounds of Formula I and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent includes 32 claims covering the compound compositions, methods of making, pharmaceutical formulations, and treatment methods.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12595248B2 to Merck Sharp & Dohme LLC for PRMT5 (protein arginine methyltransferase 5) inhibitor compounds. The patent claims 32 items covering compounds of Formula I, their pharmaceutically acceptable salts, esters, and prodrugs, along with methods of manufacturing and pharmaceutical compositions.

For pharmaceutical companies developing oncology therapeutics, this patent establishes intellectual property barriers for PRMT5 inhibitor compounds with similar structures or uses. Competitors in the cancer therapeutics space should review this patent landscape before proceeding with R&D in this area to assess freedom-to-operate implications.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

PRMT5 inhibitors

Grant US12595248B2 Kind: B2 Apr 07, 2026

Assignee

Merck Sharp & Dohme LLC

Inventors

Michelle Machacek, Michael D. Altman, Chunghui Huang, Michael H. Reutershan, David L. Sloman, Phieng Siliphaivanh, Sebastian E. Schneider, Charles S. Yeung, David J. Witter, Craig R. Gibeau, Yingchun Ye

Abstract

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

CPC Classifications

C07D 401/00 C07D 405/00 C07D 413/00 C07D 451/00 C07D 471/00 C07D 487/00 C07D 498/00

Filing Date

2020-12-14

Application No.

17783975

Claims

32

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12595248B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grants Drug development Oncology therapeutics
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!